Novel therapeutic approach for cancer using four cardiovascular hormones

European Journal of Clinical Investigation

Volumn 34, Issue 10, 2004, Pages 674-682

  Vesely, David L ^a,b   Clark, L C ^a,b   Garces, A H ^a,b   McAfee, Q W ^a,b   Soto, J ^a   Gower Jr , W R ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atrial natriuretic peptides; Cancer; Cyclic GMP; Tumour suppressors; Tumour volume

Indexed keywords

8 BROMO CYCLIC GMP; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; PEPTIDE HORMONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ATRIAL NATRIURETIC FACTOR; CELL DIVISION; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; NATRIURETIC PEPTIDES; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; TUMOR CELLS, CULTURED;

EID: 7044230856     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01402.x     Document Type: Article

References (42)

1. Pitchumoni CS. Pancreatic disease. In: Stein JH, editors. Internal Medicine. St Louis, MO: Mosby;1998.pp. 2233-47.
2. Wolff RA, Abbruzzese JL, Evans DB. Neoplasms of the exocrine pancreas. In: Holland JF, Frei E III, editors. Cancer Medicine. London, UK: BC Decker Inc; 2000.pp. 1436-64.
3. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990;70:665-99.
4. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol 2003;285:F167-F177.
5. Vesely DL. Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression. IUBMB Life 2002;53:153-9.
6. Vesely DL, Norris JS, Walters JM, Jespersen RR, Baeyens DA. Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem Biophys Res Commun 1987;148:1540-8.
7. 2-terminus are natriuretic and/or kaliuretic. Am J Physiol 1990;258:F1401-F1408.
8. 2. J Clin Invest 1992;89:1411-7.
9. Benjamin BA, Peterson TV. Effect of proANF (31-67) on sodium excretion in conscious monkeys. Am J Physiol 1995;269:R1351-R1355.
10. Dietz JR, Vesely DL, Gower WR Jr, Nazian SJ. Secretion and renal effects of ANF prohormone peptides. Clin Exp Pharmacol Physiol 1995;22:115-20.
11. Habibullah AA, Villarreal D, Freeman RH, Dietz JR, Vesely DL, Simmons JC. Infusion of atrial natriuretic factor prohormone peptides in dogs with experimental heart failure. Clin Exp Pharmacol Physiol 1995;22:130-5.
12. + reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 1995;22:121-4.
13. Villarreal D, Reams GP, Taraben A, Freeman RH. Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med 1999;221:166-70.
14. Clark LC, Farghaly H, Saba SR, Vesely DL. Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days. Am J Physiol 2000;278:H1555-H1564.
15. Dietz JR, Scott DY, Landon CS, Nazian SJ. Evidence supporting a physiologic role for proANP (1-30) in the regulation of renal excretion. Am J Physiol 2001;280:R1510-R1517.
16. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce a diuresis, natriuresis, and/or kaliuresis in humans. Circulation 1994;90:1129-40.
17. Vesely DL, Douglass MA, Dietz JR, Giordano AT, McCormick MT, Rodriguez-Paz G et al. Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 1994;78:1128-34.
18. Vesely DL, Dietz JR, Parks JR, Baig M, McCormick MT, Cintron G et al. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 1998;98:323-9.
19. Vesely DL, Dietz JR, Parks JR, Antwi EA, Overton RM, McCormick MT et al. Comparison of vessel dilator and long acting natriuretic peptide in the treatment of congestive heart failure. Am Heart J 1999;138:625-32.
20. Nasser A, Dietz JR, Siddique M, Patel H, Khan N, Antwi EK et al. Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure. Am J Cardiol 2001;88:23-9.
21. Abell TJ, Richards AM, Ikram H, Espiner EA, Yandle T. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet derived growth factor. Biochem Biophys Res Commun 1989;160:1392-6.
22. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990;86:1690-7.
23. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 1997;95:1269-77.
24. Itoh H, Pratt RE, Ohno M, Dzau VJ. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. Hypertension 1992;19:758-61.
25. Appel RG. Growth-regulatory properties of atrial natriuretic factor. Am J Physiol 1992;262:F911-F918.
26. Pedram A, Razandi M, Hu RM, Levin ER. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 1997;272:17097-103.
27. Hagiwara H, Inoue A, Yamaguchi A, Yokose S, Furuya M, Tanaka S et al. cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells. Am J Physiol 1996;270:C1311-C1318.
28. Johnson A, Lermioglu F, Garg UC, Morgan-Boyd R, Hassid A. A novel biological effect of atrial natriuretic hormone: inhibition of mesangial cell mitogenesis. Biochem Biophys Res Commun 1988;152:893-7.
29. Appel RG. Growth inhibitory activity of atrial natriuretic factor in rat glomerular mesangial cells. FEBS Lett 1988;238:135-8.
30. Vesely BA, McAfee Q, Gower WR Jr, Vesely DL. Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 2003;33:998-1005.
31. Rashed HM, Su H, Patel TB. Atrial natriuretic peptide inhibits growth of hepatoblastoma (HEP G2) cells by means of activation of clearance receptors. Hepatology 1993;17:677-84.
32. Winquist RJ, Faison EP, Waldman SA, Schwartz K, Murad F, Rapoport RM. Atrial natriuretic factor elicits an endothelium-independent relaxation and activates paniculate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci USA 1984;81:7661-4.
33. Vesely DL. Signal transduction: Activation of guanylate cyclase-cyclic GMP system by hormones and free radicals. Am J Med Sci 1997;314:311-23.
34. Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989;80:438-49.
35. Hunter EFM, Kelly PA, Prowse C, Woods FJ, Lowry PJ. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scan. J Clin Lab Invest 1998;58:205-16.
36. Franz M, Woloszczuk W, Horl WH. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int 2000;58:374-8.
37. De Palo EF, Woloszczuk W, Meneghetti M, De Palo CB, Nielsen HB, Secher NH. Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin Chem 2000;46:843-7.
38. Gower WR Jr, Risch RM, Godellas CV, Fabri PJ. HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In vitro Cell Dev Biol 1994;30A:151-61.
39. Duguay D, Mercier F, Stagg J, Martineau D, Branson J, Servant M et al. In vivo interferon regulatory factor 3-tumor suppressor activity in B16 melanoma tumors. Cancer Res 2002;62:5148-52.
40. Davis PJ, Williams SC. Protein modification by thermal processing. Allergy 1998;53:102-5. [Review].
41. Vesely DL, Cornett LE, McCleod SL, Nash AA, Norris JS. Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126. Peptides 1990;11:193-7.
42. Vesely DL, Sallman AL, Bayliss JM. Specific binding sites for pro atrial natriuretic factors 1-30, 31-67, and 99-126 on distal nephrons, proximal tubules, renal cortical and medullary membranes. Renal Physiol Biochem 1992;15:23-32.